SUTRO BIOPHARMA, INC.
STRO · XNASCIK 1382101fmd_0EYZXTCT4Y7QCKSZXWERRJGZ1QManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 60 | 52 | 38 | 43 | 43 | 62 | 68 | 154 | 62 | 102 |
| Net interest income | – | – | – | (4) | – | – | – | – | – | – |
| Research and development | 44 | 55 | 54 | 66 | 77 | 104 | 137 | 180 | 252 | 166 |
| Total operating expenses | 58 | 71 | 76 | 98 | 114 | 160 | 197 | 243 | 300 | 261 |
| Operating income | 1 | (19) | (37) | (55) | (71) | (99) | (129) | (89) | (238) | (158) |
| Interest expense | 0 | 1 | 2 | 1 | 2 | 3 | 2 | 1 | – | – |
| Other non-operating income (expense) | 0 | (0) | 2 | – | – | – | – | – | – | – |
| Income before taxes | – | – | – | – | (32) | (106) | (117) | (89) | (225) | (191) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 3 | 18 | 2 | (0) |
| Net income from continuing operations | – | – | – | – | (32) | (106) | (119) | (107) | (227) | (191) |
| Net income | 2 | (20) | (35) | (119) | (32) | (106) | (119) | (107) | (227) | (191) |